Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 397

1.

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.

Metz I, Radue EW, Oterino A, Kümpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W.

Acta Neuropathol. 2012 Feb;123(2):235-45. doi: 10.1007/s00401-011-0900-5. Epub 2011 Nov 6.

2.

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.

Mult Scler. 2013 Dec;19(14):1826-40. doi: 10.1177/1352458513510224. Epub 2013 Nov 5. Review.

PMID:
24192217
3.

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.

Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T.

J Neuropathol Exp Neurol. 2012 Jul;71(7):604-17. doi: 10.1097/NEN.0b013e31825caf2c. Review.

PMID:
22710964
4.

Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.

N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.

Clin Ther. 2016 Mar;38(3):670-5. doi: 10.1016/j.clinthera.2016.01.010. Epub 2016 Feb 5.

PMID:
26856928
5.

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M.

Ann Neurol. 2012 Nov;72(5):779-87. doi: 10.1002/ana.23676.

PMID:
23280794
6.

Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.

Wüthrich C, Popescu BF, Gheuens S, Marvi M, Ziman R, Denq SP, Tham M, Norton E, Parisi JE, Dang X, Lucchinetti CF, Koralnik IJ.

J Neuropathol Exp Neurol. 2013 Nov;72(11):1043-51. doi: 10.1097/NEN.0000000000000005.

7.

Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.

Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ.

Neurology. 2012 May 1;78(18):1390-3. doi: 10.1212/WNL.0b013e318253d61e. Epub 2012 Apr 18.

8.

Immunological and clinical consequences of treating a patient with natalizumab.

Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner MP, Jilek S, Du Pasquier RA, Gold R, Meuth SG, Ransohoff RM, Brück W, Wiendl H.

Mult Scler. 2012 Mar;18(3):335-44. doi: 10.1177/1352458511421919. Epub 2011 Sep 9.

PMID:
21908480
9.

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.

Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.

Mult Scler. 2013 Aug;19(9):1226-9. doi: 10.1177/1352458513481010. Epub 2013 Mar 18.

PMID:
23508652
10.

Progressive multifocal leukoencephalopathy after natalizumab discontinuation.

Fine AJ, Sorbello A, Kortepeter C, Scarazzini L.

Ann Neurol. 2014 Jan;75(1):108-15. doi: 10.1002/ana.24051.

PMID:
24242357
11.

Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.

Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ.

Neurology. 2012 Nov 20;79(21):2160; author reply 2160. doi: 10.1212/01.wnl.0000423208.11698.16. No abstract available.

PMID:
23170016
12.

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.

Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: Lancet Neurol. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea].

PMID:
20298967
13.

Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

Tan IL, McArthur JC, Clifford DB, Major EO, Nath A.

Neurology. 2011 Sep 13;77(11):1061-7. doi: 10.1212/WNL.0b013e31822e55e7. Epub 2011 Aug 10.

14.

MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BM, Barkhof F, Killestein J; Dutch-Belgian Natalizumab-associated PML study group.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):879-84. doi: 10.1136/jnnp-2015-311411. Epub 2015 Sep 14.

15.

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.

Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.

Neurology. 2013 Oct 15;81(16):1400-8. doi: 10.1212/WNL.0b013e3182a84101. Epub 2013 Sep 18.

PMID:
24049136
16.

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.

Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1068-74. doi: 10.1136/jnnp-2013-304897. Epub 2013 Apr 19.

17.

[Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy].

Kanda T.

Brain Nerve. 2015 Jul;67(7):891-901. doi: 10.11477/mf.1416200228. Japanese.

PMID:
26160817
18.

Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.

Tan LA, Lopes DK.

J Clin Neurosci. 2015 Oct;22(10):1669-71. doi: 10.1016/j.jocn.2015.05.003. Epub 2015 Jun 24. Review.

PMID:
26115897
19.

Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.

Sottini A, Capra R, Zanotti C, Chiarini M, Serana F, Ricotta D, Caimi L, Imberti L.

PLoS One. 2012;7(4):e34493. doi: 10.1371/journal.pone.0034493. Epub 2012 Apr 4.

20.

Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.

Wattjes MP, Barkhof F.

Curr Opin Neurol. 2014 Jun;27(3):260-70. doi: 10.1097/WCO.0000000000000099. Review.

PMID:
24739400

Supplemental Content

Support Center